Stock of the Day

November 18, 2025

Boston Scientific (BSX)

$44.10
-$0.05 (-0.1%)
Market Cap: $63.93B

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Bull Case

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • Boston Scientific Co. is currently trading at $43.78, which is near its 52-week low of $41.38, offering a potential entry point for value-oriented investors. The stock has a price-to-earnings ratio of 17.73, which is relatively low for a medical technology company, suggesting that the market may be undervaluing the company's future earnings potential compared to its historical performance.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $0.86, which beat the consensus estimate of $0.83. Revenue also exceeded expectations at $5.44 billion, up 7.5% year-over-year, indicating robust demand for its medical devices and effective execution of its business strategy.
  • Boston Scientific Co. has a low beta of 0.58, meaning its stock price tends to be less volatile than the overall market. This characteristic can make it a suitable investment for risk-averse investors or those looking to stabilize their portfolio during periods of market uncertainty.
  • The company has a strong balance sheet with a current ratio of 1.24 and a debt-to-equity ratio of 0.43, indicating good liquidity and manageable leverage. This financial health provides a buffer against economic downturns and supports the company's ability to invest in research and development.
  • Boston Scientific Co. is a leader in the medical technology sector, offering a diverse portfolio of devices for cardiovascular care, endoscopy, urology, and neuromodulation. This diversification reduces reliance on any single product line and positions the company to benefit from growing demand for minimally invasive procedures.

Boston Scientific Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • The stock has experienced a significant decline, reaching a 52-week low of $41.38, which is a substantial drop from its 52-week high of $105.65. This downward trend may indicate underlying issues with the company's business model or market conditions that could continue to pressure the stock price.
  • Analysts have recently lowered their price targets for Boston Scientific Co., with Leerink Partners cutting its target from $60.00 to $55.00 and Wells Fargo lowering its target from $50.00 to $48.00. These reductions suggest that analysts are becoming more cautious about the company's future growth prospects.
  • The company's guidance for the current fiscal year is below the consensus estimate, with Boston Scientific Co. projecting earnings per share of $3.280 to $3.320, while analysts expect $3.360. This gap may indicate that the company is facing challenges in meeting market expectations, which could lead to further stock price declines.
  • Boston Scientific Co. is facing legal challenges, including a patent infringement lawsuit against Johnson & Johnson over a heart procedure tool. Such litigation can be costly and distracting for management, potentially impacting the company's operational focus and financial performance.
  • The company is undergoing a significant organizational restructuring, including the appointment of a new COO and a split into three segments. While this may be intended to improve efficiency, such changes can introduce uncertainty and disrupt business operations, potentially affecting short-term performance.

Beware the Death Cross: 3 Stocks Triggering This Spooky Signal

Written By Dan Schmidt on 10/22/2025

Death Cross Stock Chart Grim Reaper

There are two types of Halloween people: those who like jump scares and those who don’t. But even if you’re a fan of haunted hayrides and movies like The Conjuring, you probably don’t want to ever get a jump scare from your portfolio, which is why so many investors use diversified index funds with the bulk of their wealth.

When momentum fades in a stock, the bottom can drop out quicker than the Tower of Terror. However, if you’re an active trader, you must spot signs of an ominous momentum shift before it becomes a trend. And just like a scary movie, stocks often provide hints that something nefarious is lurking.

Today, we’ll examine three companies forming a dreaded technical pattern: the Death Cross.

Death Cross Insinuates a Bearish Momentum Swing

The Death Cross is one of the more recognizable bearish signals because its appearance is always prominent and easily identified. Death Crosses form when a stock’s 50-day moving average drops below its 200-day moving average, with the two lines forming an ‘X’ on the daily chart. When the 50-day dips below the 200-day, short-term momentum is weakening, and a trend shift could be on the horizon.

Even though the Death Cross uses two long-term averages, it’s used by traders with various timelines and investment goals. Technical traders see Death Crosses as a spot to take profits or enter short positions in individual stocks or ETFs. 

Institutional investors with longer timeframes watch for the Death Cross on major indices as a ‘risk off’ signal, which means lowering exposure and sitting on more cash than usual. Death Crosses on the S&P 500 preceded long-term bear markets in 2000, 2007, and 2022.

Just because the Death Cross forms an X doesn’t mean it always marks the spot. It’s a lagging indicator, meaning stocks are often already declining by the time the alarm sounds. This scenario unfolded during the quick bear market of December 2018, where stocks started recovering by the time the Death Cross hit.

To minimize false alarms, you’ll want to use other metrics like the Relative Strength Index (RSI) or MACD to confirm the momentum shift. 

3 Death Cross Stocks Sending Scary Signals to Investors

Finding stock charts with Death Crosses is the easy part. Once you identify the signal, you must research other fundamental and technical factors. For example, a Death Cross that precedes a blowout earnings report or takeover bid will quickly be rendered moot. Each of the three stocks listed below faces some kind of fundamental or technical headwind in addition to a Death Cross.

Boston Scientific: Elevated Valuation Leaves Little Margin For Error

Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) continues to produce strong earnings beats and sales growth, but not to a level that seems to impress the market anymore.

The company beat top and bottom line estimates during its Q2 2025 report, growing sales 22% year-over-year (YOY). But the stock is down 3% over the last three months, and its 14% gain in the previous 12 months also lags major indices.

The chart highlights the market shrugging off BSX’s results, and now any remaining momentum appears to be cratering completely. The price broke through a key support level at the 50-day simple moving average (SMA), taking out the 200-day SMA on its way down.

BSX stock chart

The Death Cross appeared as the stock stabilized in October, and now the previous support levels could become resistance. BSX also faces fundamental headwinds from its heightened valuation. The stock is trading at nearly 60x earnings and 10x sales, both figures well above the medical sector average.

Darden Restaurants: Momentum Fading as Costs Rise

Popular chains like Olive Garden, Longhorn Steakhouse, Yardhouse, and Bahama Breeze all fall under the umbrella of Darden Restaurants Inc. (NYSE: DRI).

While the company does have high-end restaurants like Capital Grille in its portfolio, most of its stores are full-service casual dining, a segment that has been steadily losing market share to fast casual.

And with the costs of labor and crucial inputs like beef rising rapidly, full-service casual restaurants are struggling to keep prices competitive.

DRI stock chart DRI shares are starting to feel the pressure. The stock recently took out the 50-day SMA support level, which had been in place since the start of the year, and all upward momentum has completely dissipated. Unless the restaurant industry rebounds, DRI is likely to continue languishing.

Stryker: Strong Financial Performance Hides Weakening Momentum

Stryker Corp. (NYSE: SYK) is another medical device company of comparable size and scope to Boston Scientific.

However, Stryker has a more modest valuation and produces consistent top and bottom line earnings beats (as it did once again in Q2 2025).

So why is its stock only up 3% in the last 12 months?

The company relies on devices and tools for elective procedures, such as joint replacements.

This segment is beholden to larger macroeconomic trends and sentiment, and Stryker’s international footprint leaves it susceptible to tariffs.

Stryker stock chart

The SYK chart shows that the next few sessions will be crucial. A Death Cross is forming as the price approaches the 200-day SMA, a previous area of support, and the RSI suggests momentum is weakening. If the price is rejected at the 200-day, there’s likely more downside for SYK shares.

Recent News